Company news
Zhejiang East Asia Pharmaceutical Co., Ltd. Class A (SSE:605177) news
Zhejiang East Asia Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 11, 2026: "Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
September 10, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 8, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Semi-annual Report for 2026
August 30, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement on Implementation of Repurchase and Cancellation of Certain Restricted Shares under the Equity Incentive Plan
August 23, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Semi-annual Performance Forecast for 2026
July 14, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement on Not Revising Downward the Conversion Price of "East-Asia Convertible Bonds"
July 8, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Indicative Announcement on "East-Asia Convertible Bonds" Expected to Meet Conditions for Revising Conversion Price
July 1, 2026
"Zhejiang East-Asia Pharmaceutical Co., Ltd."Announcement on Repurchasing and Canceling Restricted Stocks Granted to Some Incentive Objects But Not Yet Lifted from Sales Restrictions
June 30, 2026
Announcement on 2026 Interest Payment of "East-Asia Convertible Bonds"
June 29, 2026
Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
June 23, 2026
Announcement on 2026 Follow-up Rating Results of Convertible Corporate Bonds Issued to Non-specific Objects
June 18, 2026
Announcement on Completing Industrial and Commercial Change Registration of Business Scope and Obtaining Renewed Business License
May 19, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 13, 2026
Announcement on Obtaining Korea Pharmaceutical Raw Material Registration Certificate for Drug Substance Vonoprazan Fumarate by its Wholly-owned Subsidiary
May 8, 2026
Report for Q1 2026
April 29, 2026
Announcement on Lifting Sales Restrictions and Listing in the 1st Lifting Period under the 2024 Restricted Stock Incentive Plan
April 27, 2026
Announcement on Renewing Engagement of Financial and Internal Control Audit Institution for 2026
April 22, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 2, 2026
Announcement on Completing the Repurchase and Cancellation of Some Restricted Stocks without Adjusting Conversion Price of Convertible Bonds
March 26, 2026
Announcement on Obtaining Drug Registration Certificate for Saxagliptin and Metformin Hydrochloride Extended-Release Tablets
March 16, 2026
Announcement on Obtaining Drug Registration Certificate for Fumonol Vonol Tablets
March 4, 2026
Announcement on Resolutions of the 14th Meeting of the 4th Board of Directors
February 6, 2026
Earnings Preannouncement for 2025
January 22, 2026
Indicative Announcement on Expected Loss in Performance for 2025
January 14, 2026
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for ""East-Asia Convertible Bonds"
December 30, 2025
Announcement on Resolutions of the 13th Meeting of the 4th Board of Directors
December 25, 2025
Announcement on Using Temporarily Idle Self-owned Funds for Entrusted Wealth Management
December 9, 2025
Announcement on Convening Performance Briefing for Q3 2025
November 11, 2025
Announcement on Adjusting the Use of the R&D Center Construction Project in the Initial Public Offering Fundraising Projects
October 30, 2025
Announcement on Receipt of Decision on Administrative Supervision Measures from Zhejiang Office of China Securities Regulatory Commission
October 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 10, 2025
Announcement on Resolutions of the 10th Meeting of the 4th Board of Directors
August 28, 2025
Announcement on the Implementation of Repurchase and Cancellation of Partial Equity Incentive Restricted Stocks
August 24, 2025
Semi-annual Earnings Preannouncement for 2025
July 14, 2025
Announcement on Wholly-owned Subsidiary Obtaining CNAS (China National Accreditation Service for Conformity Assessment) Laboratory Accreditation Certificate
July 4, 2025
Announcement on Resolutions of the 8th Meeting of the 4th Board of Supervisors
June 30, 2025
Announcement on 2025 Follow-up Rating Results of Convertible Corporate Bonds Issued to Non-specific Objects
June 27, 2025
Announcement on Obtaining the Drug Registration Certificate for Levofloxacin Tablets
June 13, 2025
Announcement on Change of Sponsor Representative for Continuous Supervision
June 3, 2025
Announcement on Postponement of Investment Projects Financed by Funds Raised from Convertible Corporate Bonds
May 30, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 20, 2025
Announcement on Obtaining Registration Certificate for Drug Substance of Trimebutine from the Republic of Korea
May 15, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
May 12, 2025
Announcement on Change of Accounting Policies
April 29, 2025
Announcement on Not Revising Downward Conversion Price of "East-Asia Convertible Bonds"
April 25, 2025
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for "East-Asia Convertible Bonds"
April 20, 2025
Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
April 9, 2025
Announcement on Wholly-owned subsidiary's Obtaining Registration Certificate for Drug Substance of Cefditoren Pivoxil from the Republic of Korea
April 1, 2025
Announcement on Establishment of Wholly-owned Subsidiary Zhejiang Shanheng Pharmaceutical Co., Ltd. and Completion of Industrial and Commercial Registration
March 10, 2025
Announcement on Change of Office Address and Contact Information
February 16, 2025